ALK and non-small cell lung carcinoma: At CLIA-certified laboratory, ExoDxTM Lung (ALK) was proved to be an accurate, real-time tool to detect EML4-ALK mutations in NSCLC patients with 88% sensitivity and 100% specificity, which provides a more direct and sensitive method to detect gene fusions than cfDNA.